-
Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista
Monday, October 3, 2016 - 11:57am | 339Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the Phase 2 CAPELLA trial of Eylea co-formulated with an anti-PDGFR-beta antibody, runicumab, did not meet the primary endpoint. Baird’s Brian P. Skorney maintained a Neutral rating on the company, with a price target of $448. He...
-
Sarepta Could More Than Double Its Addressable Market In A Few Years, But Eteplirsen Isn't The 'Be All End All'
Thursday, September 29, 2016 - 9:28am | 303Sarepta Therapeutics Inc (NASDAQ: SRPT) announced the commencement of dosing in the Phase III ESSENCE study of SRP-4045 and SRP-4053. “If the trial is successful, it could mean more than doubling of Sarepta’s addressable population in the next few years,” Baird’s Brian P...
-
FDA Rejection Of Amgen Drug Does Nothing To Change Baird's Outlook On The Stock
Friday, August 26, 2016 - 9:57am | 373Amgen, Inc. (NASDAQ: AMGN) has received a CRL [complete response letter] in relation to Parsabiv, a calcimimetic under review by the FDA for secondary hyperthyroidism. This unexpected development is likely to have only a “minimal material impact” on the stock, Baird’s Brian P....
-
Baird Still Isn't Buying Biogen
Friday, July 22, 2016 - 11:45am | 328While reporting a significant EPS beat for Q2, Biogen Inc (NASDAQ: BIIB) also announced the departure of its CEO. Baird’s Brian P. Skorney maintained a Neutral rating on the company, with a $268 price target. The stock appreciated following the announcement, since “investors have...